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Introduction
In 1957 a soluble product of inﬂ  uenza virus-infected chick 
embryo cells that conferred resistance to viral infection 
was ﬁ   rst described [1]. During the following years a 
family of cytokines capable of interfering (inhibiting) 
with viral replication was discovered in jawed vertebrates, 
and its members were deﬁ  ned as interferons [2,3]. Th  e 
family of interferons comprises type I interferons, the 
type II interferon named IFNγ and the most recently 
discovered type III interferons, termed IFNλ (IFNλ1 or 
IL-29, IFNλ2 or IL-28A and IFNλ3 or IL-28B) [4,5]. Type I 
interferons are a large group of structurally similar 
cytokines, in humans including more than 13 diﬀ  erent 
members of IFNα as well as IFNβ, IFNε, IFNκ and IFNω 
[6]. Th   e genes encoding type I interferons are clustered in 
one locus on the same chromosome (chromosome 9 in 
humans and chromosome 4 in mice), and they have been 
suggested to have diverged from a common ancestor, 
with the IFNβ gene being the primordial gene [7].
Today, more than 50 years after their discovery, type I 
interferons have been included in our therapeutic 
arma  men  tarium and are indicated for several disease 
entities [2,8]. Firstly, type I interferons are widely used for 
the treatment of chronic viral infections, mainly by 
hepatitis B virus and hepatitis C virus [2]. Several major 
break  throughs in the ﬁ   eld of interferon research have 
established the notion that type I interferons are not only 
antiviral peptides but pleiotropic cytokines. Along these 
lines it was observed that type I interferons can inhibit 
growth of some tumors by suppressing prolifera  tion and 
inducing cell apoptosis, inhibiting angiogenesis, increas-
ing immunogenicity of tumor cells and activating cyto-
toxicity against tumor cells [2]. In this context, IFNα2 is 
used in some treatment regimens for malignancies 
including chronic B-cell (hairy) leukemia, chronic myelo-
genous leukemia, myeloma, lymphomas, melanoma, 
renal-cell and bladder carcinoma and Kaposi’s sarcoma 
[2,8]. Finally, recognition of modulatory eﬀ  ects of type I 
interferons has led to the discovery that they may 
success  fully be applied in the treatment of multiple 
sclerosis (MS) [9]. Type I interferons have also been used 
in the treatment of rheumatoid arthritis (RA) and 
inﬂ  ammatory bowel disease (IBD), with more success in 
animal models than in the clinic [10-21].
In addition to the above-described beneﬁ  cial eﬀ  ects in 
infections, in malignancies and in some autoimmune/
inﬂ   ammatory diseases, there is evidence that type I 
interferons can also be detrimental for the host by 
promoting autoimmunity, inﬂ  ammation and interferon-
treatment-related toxicities in a context-dependent 
manner [1,2,22-25]. Th  e present review serves as an 
updated summary of the prevailing concepts about the 
biology of type I interferons and also provides insights for 
a better under  standing of the interferon paradox: type I 
interferons in one context promote autoimmunity and 
inﬂ  ammation, but in another context have homeostatic 
functions by restraining inﬂ   ammation and tissue 
destruction [14,26-28]. Th   is paradox is exempliﬁ  ed by the 
opposing roles of type I interferons in systemic lupus 
erythema  tosus (SLE) (probably pathogenic) [22] and in 
MS (protective and therapeutic) [9].
Type I interferon production in the context of 
infection, autoimmunity and infl  ammation
Type I interferons are produced during infection as part of 
an eﬀ   ective host defense against pathogens [3]. Type I 
interferon production is triggered by pathogen-asso  ciated 
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Type I interferons are pleiotropic cytokines with 
antiviral, antitumor and immunoregulatory functions. 
An aspect of their complex biology is the paradox 
that, depending on context, type I interferons can 
be anti-infl  ammatory and tissue protective or can 
be proinfl  ammatory and promote autoimmunity. 
Along these lines, the activation of type I interferon 
pathways is eff  ective in suppressing disease activity in 
patients with multiple sclerosis and in animal models 
of arthritis and colitis, while there is an expectation 
that blockade of the same pathways will be benefi  cial 
in the treatment of patients with systemic lupus 
erythematosus.
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lipopolysaccharide) in the context of infections. In the 
setting of SLE, type I interferons are induced by immune 
complexes containing self-derived nucleic acids [3,7,22]. 
Serum levels of type I interferons have been observed in 
patients with active SLE, and this endoge  nous type I 
interferon is believed to contribute to patho  genesis [29]. 
Interestingly, IFNβ is expressed in the inﬂ  amed synovium 
of patients with RA and at sites of central nervous system 
inﬂ   ammation in experimental autoimmune encephalo-
myelitis (EAE) [30,31]. Th   is low level of local interferon is 
suspected to represent activation of a homeostatic 
mechanism to control the intensity of inﬂ  ammation and 
to restrain the extent of tissue destruction [14,32]. 
Inﬂ  ammatory stimuli (including the cytokines TNFα and 
RANKL) produced in the microenvironment of the 
synovium and central nervous system may contribute to 
the local expression of type I interferons during RA and 
EAE [33,34].
Indispensable for induction of expression of type I 
interferons is the balanced activation of several trans  crip-
tion factors, including interferon regulatory factors 
(IRFs), NF-κB and AP-1 [7]. IRFs are considered key 
transcription factors for induction of type I interferons. 
Th   ey are activated by kinases in a cell-type-speciﬁ  c and 
stimulus-speciﬁ   c manner. IRF-3 is constitutively 
expressed and, following activation, potently activates the 
IFNβ gene. IRF-7 is highly expressed in plasmacytoid 
dendritic cells (DCs) and is induced by type I interferons; 
it eﬃ   ciently activates both IFNα and IFNβ genes, and can 
serve as part of an ampliﬁ  cation loop to augment type I 
interferon production [35]. IRF-1 has been implicated in 
low-level induction of IFNβ by TNFα [33]. Evidence 
indicates that certain IRF-5 mutations, by regulating 
interferon type I activity, confer susceptibility to SLE [36, 
37]. Finally, c-Fos, the partner of c-Jun in the trans-
cription factor AP-1, drives production of IFNβ down-
stream of RANKL signaling [34].
In the setting of infection, recognition of pathogen-
derived nucleic acids by speciﬁ  c sensors within the host’s 
cells is a major stimulus for the production of type I 
interferons (Figure 1) [3,7]. According to a recent report, 
binding of the nucleic acids to high-mobility group box 
(HMGB) proteins is required for their eﬃ   cient recog-
nition by the host’s sensors [38]. Two intracellular sys-
tems account for sensing nucleic acids that induce type I 
interferons: one is Toll-like receptor (TLR) dependent 
and is restricted to endosomes of specialized sentinel 
cells (monocytes, macrophages and DCs); the other is 
cytosolic and is ubiquitously expressed [3,7].
Th  e TLR-dependent interferon-inducing system com-
prises TLR3, TLR7/8 and TLR9, which speciﬁ  cally sense 
dsRNA, ssRNA and DNA (hypomethylated CpG DNA), 
respectively. Th  e cytosolic sensing system includes the 
retinoic acid inducible gene (RIG)-like receptors RIG-I 
and melanoma diﬀ  erentiation-associated protein 5 (MDA5), 
which are sensors of cytosolic RNA [7], the DNA-sensing 
receptor DAI (DNA-dependent activator of IRFs) [39], 
and RNA polymerase III, which transcribes cytosolic 
DNA into RNA that is sensed by RIG-like receptors 
[40,41]. In general, the binding of the endosomal or 
cytosolic receptors with the high-mobility group box–
nucleic acid complexes leads to recruitment of adaptor 
molecules (TRIF/TRAF3/NAP1 for TLR3, MyD88 for 
TRL7/8 and TLR9, and IPS1/TRAF3 for RIG-I and 
MDA5). In a cell-type-speciﬁ   c and stimulus-speciﬁ  c 
manner, kinases (TBK1, IRAK1, IKKα, IKKε and phos-
phoinositide 3-kinase (PI3K)) are then recruited that 
phosphorylate serine and threonine residues on the latent 
IRFs. Activated IRFs form homodimers or heterodimers, 
translocate to the nucleus and bind to regulatory 
elements in the promoter regions of type I interferon 
genes, triggering transcription [7]. Although any nucleated 
cell has the capacity to produce type I interferons upon 
appropriate stimulation, prolonged endosomal retention 
Figure 1. Pathways (receptors and ligands) leading to type I 
interferon production. DAI, DNA-dependent activator of interferon 
regulatory factors; HMGB, high-mobility group box protein; LPS, 
lipopolysaccharide; MDA5, melanoma diff  erentiation-associated 
protein 5; RIG-I, retinoic acid inducible gene I; TLR, Toll-like receptor.
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TLR9 and IRF-7 render plasma  cytoid DCs the most 
powerful producers of type I inter  ferons [7].
Type I interferon production can also be induced by 
non-nucleic acid pathogen-derived molecular patterns 
(Figure  1). Recognition of lipopolysaccharide by TLR4 
triggers the activation of IRF-3 by TBK1 kinase and 
results in production of IFNβ [42]. Th  is pathway is 
dependent on recruitment to the intracellular domain of 
TLR4 of the adaptor molecules TRAM, TRIF, TRAF3 
and NAP1. It has recently been reported that TLR2 
ligands of viral origin, but not those of bacterial origin, 
induce type I interferons in a MyD88/IRF-3/IRF-7-
depen  dent manner [43]. Traﬃ   cking of TLR2 and TLR4 
from the plasma membrane to the endosomal compart-
ment is required for induction of type I interferon 
[42,43]. Interestingly, monocytes are a key source of 
TLR2-induced type I interferons in vitro and in vivo [43]. 
Since monocytic cells outnumber plasmacytoid DCs in 
vivo, the latter may not be the major source of type I 
interferons  in vivo. Indeed, monocytic cells have been 
identiﬁ  ed as the major source of type I interferons in 
animal models of infection [44] and of lupus [45].
In SLE, excess apoptosis and tissue damage combined 
with decreased clearance of apoptotic bodies probably 
result in an increased load of immunogenic self-nucleic 
acid-containing particles [22]. Circulating autoantibodies, 
speciﬁ  c for nucleic acids or nucleoproteins, form immune 
complexes with the particles. Th  ese complexes are 
captured by receptors – for example, FcγRIIa – expressed 
on the surface of sentinel cells (monocytes, macrophages 
and DCs), gain access to the intracellular compartment, 
and are recognized by the endosomal and cytosolic 
system that trigger type I interferon production [22].
Signaling pathways of type I interferons: not only 
Jak-STAT
Th  e pleiotropic functions of type I interferons mirror a 
complexity of intracellular signaling pathways [6]. Th  e 
type I interferons all utilize a ubiquitously expressed 
hetero  dimeric IFNα/β receptor (IFNAR) and generate 
similar, although not necessarily identical, signals [4].
IFNAR consists of IFNAR1 and IFNAR2 subunits that 
are associated with cytoplasmic protein tyrosine kinases 
Tyk2 and Jak1, respectively. IFNAR2 is also constitutively 
associated with STAT2. Ligation of IFNAR results in 
activation of Tyk2 and Jak1, and in phosphorylation of 
tyrosine residues in the IFNAR cytoplasmic domains, 
thus creating docking sites for signal transducers and 
activa  tors of transcription (STATs), including STAT2 and 
proabably STAT1. Both STAT1 and STAT2 are activated 
at the IFNAR signaling complex by tyrosine phos-
phorylation, with subse  quent formation of STAT1:STAT2 
heterodimers and STAT1:STAT1 homodimers [46].
Th   ese STAT proteins translocate to the nucleus, where 
STAT1:STAT1 homodimers bind to gamma-activated 
sequence (GAS) sites (consensus sequence TTCNNNGAA) 
in gene promoters and activate transcription. In contrast, 
STAT1:STAT2 heterodimers associate with IRF9 to form 
the ISGF3 complex that binds to an interferon-stimulated 
response element (ISRE) site (consensus sequence TTT-
CNN  TTTC) [4,46]. Type I interferons thus activate 
expression of genes that have either GAS or ISRE sites, or 
both, in their promoters [2,46,47]. ISGF3 and cognate 
interferon-stimulated response elements play a key role 
in activation of antiviral genes and antiviral responses, 
whereas gamma-activated sequence elements mediate 
induction of inﬂ   ammatory genes such as chemokines. 
Type I interferons can also activate STAT3 and, in a cell-
type-speciﬁ  c manner, STAT4, STAT5 and STAT6 [47]. 
In addition to the classical Jak-STAT pathway, other 
signaling pathways – including the mitogen-activated 
protein kinase pathways and the PI3K pathways – are 
activated by type I interferons [6]. Th  ese nonclassical 
signaling pathways are activated in a stimulus-speciﬁ  c 
and cell-type-speciﬁ   c manner downstream of IFNAR. 
Th  ere is evidence that the cytoplasmic protein tyrosine 
kinases Tyk2 and Jak1 are actively implicated in the 
induction of the nonclassical signaling pathways. For 
example, they phosphorylate the insulin receptor sub-
strates 1 and 2, providing a docking site for the regulatory 
domain of PI3K (p85), and they activate upstream 
regulators of p38, triggering activation of the PI3K and 
p38 pathways, respectively. Th   e biologic consequences of 
the activation of these nonclassical signaling pathways 
have been reviewed recently [6].
Type I interferons as boosters of immune 
responses: implication in SLE pathogenesis
Type I interferons are constitutively expressed at low 
levels; expression is rapidly enhanced upon viral or bac-
terial infection, aiming for an eﬀ  ective immune response 
against the pathogens [3,35]. Type I interferons induce an 
antiviral state in cells by suppressing mecha  nisms for 
viral replication, trigger apoptosis in virally infected cells, 
promote natural killer cell-mediated and CD8+ T-cell-
mediated cytotoxicity, promote the transition from 
innate to acquired immunity by augmenting DC matura-
tion, cross-presentation of antigens and migration, and 
enhance T-helper type 1 responses, generation of T 
follicular helper cells, and humoral responses [3,8,48-51].
Mounting observations indicate that type I interferons 
are implicated in the pathogenesis of several diseases, 
with autoimmune characteristics including SLE, primary 
Sjögren’s syndrome, dermatomyositis, scleroderma and 
insulin-dependent diabetes mellitus [24]. Th   e role of type I 
interferons in SLE pathogenesis is now a well-estab  lished 
notion that has been supported by several lines of 
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Serum levels of IFNα in SLE patients can be as high as 
levels achieved during acute viral infections, and a 
positive correlation between serum IFNα levels and 
disease severity has been described [29,52]. Additionally, 
gene expression proﬁ  ling with microarrays and real-time 
PCR demonstrated an IFNα signature in peripheral blood 
cells of SLE patients that was correlated with disease 
activity [53,54]. Interestingly, IFNα therapy in the setting 
of cancer or chronic viral infection induces autoantibody 
formation in 4 to 19% of patients and occasionally induces 
SLE-like symptoms [22,25]. Finally, IFNα administration 
in lupus-prone mice accelerates disease, and deletion of 
IFNAR substantially decreases morbidity and prolongs 
survival in these animals [24,55]. SLE is characterized by 
autoimmunity and organ inﬂ   ammation. Type I inter-
ferons may contribute to disease pathogenesis by 
promoting either autoimmunity or inﬂ  ammation, or both 
(Figure 2, left-hand side) [22,23,46].
One mechanism by which type I interferons may 
promote autoimmunity, driving SLE pathogenesis, 
consists of abrogating peripheral tolerance to auto-
antigens through activation of immature DCs [22]. 
Normally, autoreactive lymphocytes that have escaped 
from the central checkpoint of the thymus are controlled 
in the periphery by immature DCs lacking co-stimulatory 
molecules. DCs capture, process and present antigens in 
association with MHC molecules to lymphocytes. 
Antigen presentation by immature DCs leads to toler-
ance. Type I interferons promote maturation of DCs 
through induction of MHC II molecules, as well as CD40, 
CD80 and CD86 co-stimulatory molecules. Sera from 
patients with active SLE promote in vitro maturation of 
DCs, and blood monocytes derived from these patients 
exhibit DC-like properties such as enhanced antigen 
presentation and co-stimulatory capacity [29]. During 
the course of SLE, tissue damage and decreased clearance 
of apoptotic bodies generate an excess of autoantigens. 
Augmented levels of type I interferons may promote a 
break of tolerance to these autoantigens, thus driving 
autoimmunity (by allowing activation of autoreactive 
lymphocytes by interferon-activated DCs) [22].
A hallmark of SLE is the presence of autoantibodies, 
including antinuclear antibodies, antibodies directed to 
cell surface molecules (on erythrocytes, platelets, 
neurons), antibodies against proteins bound to phospho-
lipids and antibodies against antigens expressed in target 
organs like the kidney [22]. Type I interferons, via 
complex mechanisms, enhance antibody responses 
(adjuvant activity) and promote long-term antibody 
production, class switching and immunological memory 
[48-51]. Recently it has been reported that type I 
interferons stimulate generation of germinal centers by 
targeting DCs and stromal cells to promote development 
of T follicular helper cells [48]. Th  e T follicular helper 
cells repre  sent a distinct T-helper cell population 
restricted to draining lymph nodes and specialized in 
supporting diﬀ  eren  tiation of germinal center B cells, a 
mandatory process for production of class-switched IgG 
[48]. Additionally, type I interferons stimulate production 
of B-cell activating factor belonging to the TNF family 
(BAFF), of a proliferation-inducing ligand (APRIL), and 
of IL-6 – all of which promote B-cell survival and 
diﬀ  erentiation to plasma  blasts and antibody-producing 
plasma cells [22,50].
Several investigators, including our group, have con-
sidered the possibility that type I interferons may contri-
bute to SLE pathogenesis by bolstering inﬂ  ammatory 
responses through priming of myeloid cells (DCs and 
macrophages) and by inducing high-level STAT1 
expression [46]. Th   e concept of priming is a key aspect of 
interferon biology and is deﬁ  ned as pre-exposure to low 
concentrations of interferons leading to enhanced 
responses to minor subsequent stimuli (including infec-
tions, autoantigens, environmental antigens, components 
of damaged tissues, or cytokines) [35]. Th  e classical 
function of priming is to potentiate innate immune res-
ponses during the early phase of infections when cyto  kine 
concentrations are low, thereby enhancing host defense. A 
common theme is that priming results in increased 
activation of STAT1, with its attendant inﬂ  ammatory 
actions. STAT1 further ampliﬁ   es cell activation by 
activating STAT1-mediated feedforward mechanisms 
(described below) and by counteracting feedback 
pathways such as those mediated by suppressor of 
cytokine signaling (SOCS) proteins or STAT3 [46].
A substantial body of data supports the notion that 
priming of immunocytes occurs in SLE and other 
rheumatic diseases and contributes to disease patho-
genesis. As previously noted, type I interferons are 
expressed in SLE at levels that would be expected to elicit 
priming [29]. Furthermore, leukocytes isolated from SLE 
patients have been found to express increased levels of 
STAT1, a key marker in interferon priming. Interestingly, 
with the use of corticosteroids, suppression of STAT1 
expression occurs concomitantly with demonstrated 
clinical improvement in SLE patients, thereby providing a 
possible mechanism of action for this drug class in 
systemic lupus [23]. Isolated monocytes of SLE patients 
who had not undergone treatment displayed an enhanced 
response to TLR activators (such as lipopolysaccharide) 
and IL-1β, potentially as a result of in vivo interferon-
mediated priming [46]. By priming the host response, 
type I interferons can, in turn, enhance and modulate the 
inﬂ  ammatory cellular responses to other molecules long 
implicated in modulating the pathogenesis of auto-
immune diseases, such as TNF, IL-1 and IL-6, IFNγ, and 
TLRs [23,35,46,47].
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how exposure to interferons sensitizes cells to subsequent 
stimuli. Stimulation with type I interferons potentiates 
the physical association between IFNAR1 and IFNGR2 
or gp130 [35]. Formation of such receptor complexes 
(receptosomes) increases the docking sites for STATs, 
resulting in more eﬃ   cient dimerization of these STATs 
and enhanced responses to IFNγ and IL-6. Another 
mechanism of priming with relevance to SLE is that type 
I interferons induce increased expression of TLR3, TLR7 
and TLR9, thus sensitizing cells to nucleic acid stimu-
lation. As previously noted, a key feature of interferon 
priming is the increased expression of STAT1 [56]. 
Increased intracellular availability of STAT1 results in 
increased STAT1 phosphorylation downstream of 
IFNGR and IL-6 receptors, resulting in enhanced cellular 
activation in response to IFNγ and IL-6 stimulation 
[46,47,57]. An additional aspect of the biological 
consequences of the high intracellular levels of STAT1 is 
the perturbation of IL-10 signaling and function. IL-10, a 
powerful anti-inﬂ  ammatory cytokine, is a potent activa-
tor of the anti-inﬂ  ammatory STAT3 and a weak activator 
of STAT1 in myeloid cells, and does not normally induce 
STAT1 target genes as does IFNγ. Pre-exposure to type I 
interferons, however, reprograms STAT activation by IL-
10 such that STAT1 is more strongly activated by IL-10 in 
these cells, resulting in induction of a group of STAT1-
dependent genes and thereby a gain of inﬂ  ammatory 
function [56].
Additional mechanisms by which type I interferons 
may promote inﬂ   ammation and tissue damage in the 
context of SLE include the induction of pathogenic 
complement-ﬁ  xing antibodies and production of chemo-
kines that recruit inﬂ  ammatory cells at sites of immune 
complex deposition [23]. It is also interesting to consider 
the possibility that type I interferons may have pathogenic 
eﬀ  ects by acting on cells in target organs. Recent evidence 
from our and other laboratories has demonstrated an 
interferon signature in the kidneys in murine lupus 
nephritis that is associated with macrophage inﬁ  ltration 
and proliferative nephritis [58,59]. Our study provides in 
vivo evidence that IFNα increases matrix metallo-
proteinase activation and growth factor expression to 
promote glomerular cell proliferation and early ﬁ  brosis. 
Th  is process was mediated by alternatively activated 
macrophages expressing a dysregulated tissue repair 
program [58].
A role for type I interferons in attenuation of 
infl  ammation and tissue destruction
Although an interferon signature has been observed in 
peripheral blood cells derived from a subgroup of 
patients with MS and active RA [60-62], there is evidence 
suggesting that type I interferons are therapeutic in MS 
and are potentially beneﬁ  cial for RA and IBD by reining 
inﬂ   ammation and tissue destruction. Firstly, IFNβ has 
been shown to reduce attack frequency in patients with 
MS and has become the established treatment of choice 
for the relapsing remitting form of MS [9]. Additionally, 
in animal models of inﬂ  ammatory arthritis, MS (EAE) 
and IBD, administration or triggered production of 
IFNα/β or IFNβ gene therapy has been shown to reduce 
disease severity [10,11,13,15,16,20,63,64], while the lack 
of type I interferon signaling (IFNAR1 knockout or IFNβ 
knockout) resulted in more severe disease manifestation 
[15,16,20,31,65,66].
Various mechanisms have been proposed to explain 
such anti-inﬂ  ammatory and tissue-protective eﬀ  ects of 
type I interferons (Figure 2, right-hand side) [14,26-28]. 
Reports suggest that type I interferons regulate the 
inﬂ   am  matory milieu by increasing expression of anti-
inﬂ   am  matory factors (including IL-10, IL-27, trans-
forming growth factor beta, IL-1R antagonist, soluble 
TNF receptors, suppressor of cytokine signaling) and 
decreasing proinﬂ  ammatory mediators (including IL-1, 
IL-6, IL-8, IL-12, IL-18, TNFα, IFNγ, osteopontin, prosta-
glandin E and cyclooxygenase-2) [8,14,26,28,67]. It is 
important to emphasize that type I interferons modulate 
the inﬂ   am  matory microenvironment in a context-
dependent manner and not uniformly. Th  us, adminis-
tration of IFN-β in mice with collagen-induced arthritis 
resulted in signiﬁ  cant decrease in synovial expression of 
TNF-α and IL-6 [13], while in rats with adjuvant-induced 
arthritis expression of IL-1β but not TNF-α and IL-6 was 
reduced [64].
Type I interferons suppress production of proinﬂ  am-
matory cytokines both at the level of transcription and at 
the level of mRNA stability. One mechanism may be the 
capacity of type I interferons to suppress key trans-
cription factors for induction of proinﬂ  ammatory cyto-
kines (including NF-κB, AP-1 and PU.1) [13,23]. In a 
study from our laboratory, IFNα also suppressed TNFα 
production by inducing expression of the tyrosine kinase 
Axl that in turn induced expression of Twist, a trans-
criptional repressor of the TNFα promoter [68]. Inter-
feron-induced Axl and related TAM kinases have been 
implicated in feedback suppression of TLR responses by 
a SOCS1-mediated mechanism [69]. Additionally, type I 
interferons induce the expression of an RNA-binding 
protein named tristetraprolin, which destabilizes trans-
cripts of proinﬂ   ammatory cytokines (including TNFα 
and IL-6) by mediating mRNA decay [70].
Evidence also indicates that type I interferons not only 
suppress production but also inhibit the function of 
proinﬂ  ammatory mediators. Our group observed, using 
an in vitro system, that IFNα attenuates IL-1β pro  inﬂ  am-
matory eﬀ  ects by downregulating the expression of the 
signaling receptor IL-1RI [71], and others have found that 
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by a PI3K-mediated mechanism [72].
Interestingly, accumulating evidence indicates that type 
I interferons suppress T-helper type 17 (Th  17) cell 
develop  ment [66,67,73-75]. In animal models of arthritis 
(collagen-induced arthritis) and central nervous system 
inﬂ  ammation (EAE), Th   17 cells are principal drivers for 
disease pathogenesis. Th   eir patho  genic role has also been 
suspected in human diseases including RA, MS, IBD, 
psoriasis, juvenile diabetes and autoimmune uveitis. It 
has been suggested that type I interferons suppress Th  17 
cell generation by modulating the cytokine micro-
environment that determines the fate of T-helper cells. 
Type I interferons – by targeting antigen-presenting cells 
(monocytes, macrophages and DCs) – increase the 
production of IL-27, which is a potent inhibitor of Th  17, 
and decrease IL-1β, trans  forming growth factor beta 1 
and IL-23, which favor Th  17  diﬀ  erentiation [66,67,74,75]. 
A recent report indicates that type I interferons induce 
the production of IL-27 in DCs by downregulating the 
intracellular isoform of osteopontin (Opn-i) [67].
Th  e anti-angiogenic eﬀ  ect of type I interferons may 
represent another mechanism contributing to the bene-
ﬁ   cial function of type I interferons in the context of 
inﬂ  ammatory arthritis, where increased vascularization 
is a prominent component of synovial pathology [14]. 
Figure 2. Context-dependent eff  ects of type I interferons. In the context of systemic lupus erythematosus (SLE) (left-hand side), type I 
interferons are probably pathogenic by the following mechanisms: (1) augmenting humoral responses and production of complement-fi  xing 
pathogenic antibodies (induce generation of T follicular helper cells (Tfh), stimulate formation of germinal centers and enhance survival of B 
cells and diff  erentiation to plasmablasts and antibody-producing plasma cells); (2) activating immature dendritic cells (DCs), braking peripheral 
tolerance to self-antigens; (3) promoting T-helper type 1 (Th1) diff  erentiation; (4) promoting natural killer (NK) cell-mediated and CD8-mediated 
cytotoxicity; (5) inducing production of chemokines that recruit infl  ammatory cells at sites of immune complex deposition; and (6) priming myeloid 
cells for enhanced responses to infl  ammatory stimuli. In the context of multiple sclerosis (MS), rheumatoid arthritis (RA) and infl  ammatory bowel 
disease (IBD) (right-hand side), type I interferons are potentially anti-infl  ammatory and tissue protective by: (1) inhibiting generation of Th17 cells; 
(2) increasing anti-infl  ammatory mediators and decreasing proinfl  ammatory mediators; (3) suppressing angiogenesis; (4) reducing tissue invasion of 
infl  ammatory cells; (5) shifting the balance of proteases versus protease inhibitors in favor of inhibitors; and (6) suppressing osteoclastogenesis. Ab, 
antibody; STAT = signal transducer and activator of transcription.
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by targeting nonendothelial cells or directly by targeting 
endothelial cells. In nonendothelial cells, type I inter-
ferons decrease the production of angiogenesis-promot-
ing factors (including basic ﬁ  broblast growth factor and 
vascular endothelial growth factor) and induce angio-
static chemokines [14]; in endothelial cells, type I inter-
ferons trigger an antiangiogenic program of gene expres-
sion [76] and suppress proliferation of endothelial cells 
and their progenitors [77].
Another important facet of the homeostatic function of 
type I interferons is their capacity to protect tissue 
integrity and restrain damage. IFNβ preserves the integrity 
of the blood–brain barrier and attenuates demyelination in 
EAE [31,32], and prevents destruction of cartilage and 
bone in animal models of arthritis [14]. Proposed 
explanations for this tissue protection have been that type 
I interferons regulate inﬂ   ammatory cell traﬃ   cking, 
modulate the balance between proteases and protease 
inhibitors and inhibit osteoclastogenesis [14,26,28]. Type I 
interferons restrict tissue invasion of inﬂ  ammatory cells by 
regulating the expression of adhesion molecules 
(downregulate expression on the cell surface and 
upregulate soluble forms of adhesion molecules) and by 
reducing MMP-9, which degrades extracellular matrix and 
facilitates tissue entrance of inﬂ   ammatory cells [14]. 
Finally, type I interferons are powerful inhibitors of 
osteoclastogenesis by decreasing expression of c-Fos, an 
essential transcription factor required for osteoclasto-
genesis induced downstream of RANKL [34]. Additional 
mechanisms that contribute to the anti-osteoclastogenic 
eﬀ  ects of type I interferon may include an inhibitory eﬀ  ect 
on the expression of osteoclastogenic TNFα and IL-1β and 
decreased c-Cbl and Cbl-b expression [64].
Concluding remarks
It is clear that type I interferons can either promote or 
suppress immune and inﬂ  ammatory responses and auto-
immune diseases, depending on the context (Figure 2). 
Several explanations for the pleiotropic and paradoxical 
nature of interferon activity in diﬀ   erent immune res-
ponses and autoimmune diseases have been proposed. 
Th  ese include diﬀ   erent biological activities based on 
timing, diﬀ   erent concentration-dependent eﬀ  ects,  the 
location of expression and eﬀ  ects on cells that make up 
target organs, and diﬀ  erential eﬀ  ects on immunity versus 
inﬂ   ammation or on innate immunity versus acquired 
immunity [46,47]. In addition, type I interferon activity 
and signaling are regulated and reprogrammed during 
immune and inﬂ  ammatory responses, with alterations in 
the balance between activation of STAT1 and STAT3 or 
STAT4 [78,79]. An alternative nonmutually exclusive 
explanation proposes an interferon–TNF axis in which 
each cytokine is pathogenic in diﬀ  erent diseases and in 
which interferons and TNF cross-inhibit each other’s 
expression [22]. Emerging evidence supports a complex 
crossregulation between interferons and TNF, including 
induction of interferons by TNF in certain cell types [33] 
and extensive crosstalk at the level of signal transduction.
Blockade of type I interferon pathways has emerged as 
an attractive therapeutic approach for SLE [22,24], while 
activation of the same pathways has proven clinically 
eﬀ  ective in a subset of patients with MS [9] and in animal 
models of RA and IBD [14,20]. Th  is distinction reﬂ  ects 
an interferon paradox and raises the question of how we 
can target interferon pathways (block or trigger) in such a 
way that detrimental eﬀ   ects are minimized while 
beneﬁ  cial eﬀ  ects, including a key role in antiviral host 
defense, are preserved. Th  erapeutic approaches that 
target speciﬁ   c interferon-induced signaling pathways 
may be beneﬁ  cial. For example, selective inhibition of 
proinﬂ   ammatory STAT1 activation while preserving 
ISGF3 activation and antiviral responses may represent a 
fruitful approach [78]. A better understanding and 
charac  terization of the molecular mechanisms that 
regulate type I interferon signaling and downstream 
target genes (for example, by applying bioinformatics) 
will set the stage for selective manipulation of interferon 
pathways without the risk of compromising homeostatic 
functions or host defense.
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